There is evidence that serotonin may be implicated in the pathophysiol
ogy of myofascial pain (MFP). Because of this, we used oral sumatripta
n (Imitrex, Glare), a peripherally acting agonist of 5-HT1D receptors,
in a double-blind, randomized, placebo-controlled double crossover pi
lot study of 7 patients with episodic MFP of the temporalis muscles. T
he results showed that there was a significant reduction in pain inten
sity and increase in pain relief over time with both the active medica
tion and the placebo, but no significant difference between treatments
. All but 1 patient reported that they are not interested in retaking
the same medication. These data suggest that oral sumatriptan may not
be the drug of choice in the control of episodic MFP.